Schizophrenia Clinical Trials

83 studies are recruiting for schizophrenia in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

   This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Neurocrine Clinical Site, Bryant, Arkansas

   Locations

   19 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07105111 on ClinicalTrials.gov

2. A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia

   The purpose of this clinical trial is to learn whether the investigational drug LTX-001 is safe and well tolerated in adults with a diagnosis of schizophrenia who are having a recent worsening of their symptoms (an acute exacerbation). Additional questions it aims to answer are: * how does the amou…

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   Pillar Clinical Research, LLC, Little Rock, Arkansas

   Locations

   10 in total

   Run by

   Leal Therapeutics, Inc

   See if you can join NCT07734493 on ClinicalTrials.gov

3. Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)

   Patients with schizophrenia spectrum disorder (SSD) will be exposed to active repetitive transcranial magnetic stimulation (rTMS) from F8 coil or active rTMS from H coil for smoking cessation. Smoking and brain functional connectivity changes will be assessed at baseline, different stages of rTMS a…

   Stage

   Not phased

   Ages

   22 to 65

   Site

   The University of Texas Health Science Center, Houston, Houston, Texas

   Run by

   The University of Texas Health Science Center, Houston

   See if you can join NCT05276050 on ClinicalTrials.gov

4. A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

   Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult part…

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Woodland International Research Group /ID# 275747, Little Rock, Arkansas

   Locations

   7 in total

   Run by

   AbbVie

   See if you can join NCT07145918 on ClinicalTrials.gov

5. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

   The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Pillar Clinical Research - Bentonville, Bentonville, Arkansas

   Locations

   59 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07686263 on ClinicalTrials.gov

6. 52-week Open Label Safety-Tolerability Study

   Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Chandler Clinical Trials, Chandler, Arizona

   Locations

   23 in total

   Run by

   LB Pharmaceuticals Inc.

   See if you can join NCT07369154 on ClinicalTrials.gov

7. A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

   The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.

   Stage

   Phase 3

   Ages

   13 to 17

   Site

   Advanced Research Center Inc., Anaheim, California

   Locations

   38 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07288567 on ClinicalTrials.gov

8. A Study of Brenipatide in Adult Participants With Schizophrenia

   The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment pe…

   Stage

   Phase 2

   Ages

   18 to 55

   Site

   Pillar Clinical Research- Little Rock, Little Rock, Arkansas

   Locations

   103 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07410507 on ClinicalTrials.gov

9. Genetic Basis of the Risk and Consequences of Cannabis Exposure in Humans

   Cannabis is widely used worldwide and is associated with negative outcomes including cannabis use disorder (CanUD), psychosis, and cognitive impairment amongst others. Given the legalization of "recreational" and "medical" cannabis globally, the increasing availability of cannabis, the higher poten…

   Stage

   Phase 1

   Ages

   21 to 60

   Site

   West Haven Veterans Affairs Medical Center, West Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT06058702 on ClinicalTrials.gov

10. A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

    A study to evaluate the safety, tolerability, and PK of an injectable form of KarXT in participants with schizophrenia

    Stage

    Phase 1

    Ages

    18 to 55

    Site

    Collaborative Neuroscience Research, LLC, Los Alamitos, California

    Locations

    8 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07061288 on ClinicalTrials.gov

11. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

    ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

    Stage

    Phase 2

    Ages

    18 to 65

    Site

    Clinical Site, Little Rock, Arkansas

    Locations

    42 in total

    Run by

    MapLight Therapeutics

    See if you can join NCT07459647 on ClinicalTrials.gov

12. Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls

    This study to find out whether a type of non-invasive electrical brain stimulation called transcranial electrical stimulation with temporal interference (TES-TI) can temporarily change brain activity during sleep-especially sleep spindles (brain rhythms in the ~8-16 Hz range). The investigators are…

    Stage

    Not phased

    Ages

    18 to 50

    Site

    University of Wisconsin, Madison, Wisconsin

    Run by

    University of Wisconsin, Madison

    See if you can join NCT07680114 on ClinicalTrials.gov

13. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

    This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

    Stage

    Phase 3

    Ages

    5 to 17

    Site

    Southwest Autism Research and Resource Center, Phoenix, Arizona

    Locations

    64 in total

    Run by

    Intra-Cellular Therapies, Inc.

    See if you can join NCT06229210 on ClinicalTrials.gov

14. A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively

    The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively

    Stage

    Phase 3

    Ages

    5 to 17

    Site

    Advanced Research Center Inc., Anaheim, California

    Locations

    91 in total

    Run by

    Karuna Therapeutics, Inc., a Bristol Myers Squibb company

    See if you can join NCT07424404 on ClinicalTrials.gov

15. A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

    The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and tolerable aticaprant is when compared with placebo in participants with schizophrenia.

    Stage

    Phase 1

    Ages

    18 to 55

    Site

    CNS Network, Garden Grove, California

    Locations

    8 in total

    Run by

    Janssen Research & Development, LLC

    See if you can join NCT07615426 on ClinicalTrials.gov

16. Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

    The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by Positive and Negative Syndrome Scale (PANSS) total score in participants with schizophrenia.

    Stage

    Phase 2

    Ages

    18 to 60

    Site

    TG Therapeutics Investigational Trial Site, Little Rock, Arkansas

    Locations

    2 in total

    Run by

    TG Therapeutics, Inc.

    See if you can join NCT07680946 on ClinicalTrials.gov

17. Cerebellar Modulation of Cognition in Psychosis

    The goal of this clinical trial is to learn about cognition in psychotic disorders (schizophrenia, bipolar disorder, and schizoaffective disorder). The main question it aims to answer is: Can we use magnetic stimulation to change processing speed (how quickly people can solve challenging tasks). Pa…

    Stage

    Not phased

    Ages

    18 to 55

    Site

    McLean Hospital, Belmont, Massachusetts

    Locations

    2 in total

    Run by

    Mclean Hospital

    See if you can join NCT06107764 on ClinicalTrials.gov

18. Enhancing Veteran-Clinical Collaboration in VA PRRCs

    Over 60% of Veterans with serious mental illness have a service-connected disability that impairs their ability to work, go to school, and/or have successful personal lives. Although traditional treatments tend to focus on symptom remission, Veterans prioritize a range of treatment goals, including…

    Stage

    Not phased

    Ages

    18 and older

    Site

    New Mexico VA Health Care System, Albuquerque, NM, Albuquerque, New Mexico

    Locations

    3 in total

    Run by

    VA Office of Research and Development

    See if you can join NCT06898879 on ClinicalTrials.gov

19. Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

    The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy

    Stage

    Not phased

    Ages

    18 and older

    Site

    ATP Clinical Research, Costa Mesa, California

    Locations

    20 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07101094 on ClinicalTrials.gov

20. Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

    The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

    Stage

    Not phased

    Ages

    18 and older

    Site

    SanRo Clinical Research Group, Bryant, Arkansas

    Locations

    55 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07379827 on ClinicalTrials.gov

21. REACH Study (Recovery Environments: Assessing Cognitive & Brain Health in Community Mental Health)

    The purpose of this study is to understand how different types of community-based mental health care affect thinking abilities, daily functioning, and brain activity in adults with schizophrenia and related conditions. The investigators are especially interested in learning whether the Clubhouse Mo…

    Stage

    Not phased

    Ages

    18 to 50

    Site

    Case Western Reserve University, Cleveland, Ohio

    Run by

    Case Western Reserve University

    See if you can join NCT07006935 on ClinicalTrials.gov

22. Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

    To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine

    Stage

    Phase 3

    Ages

    10 to 17

    Site

    Alkermes Investigator Site, Dothan, Alabama

    Locations

    47 in total

    Run by

    Alkermes, Inc.

    See if you can join NCT05303064 on ClinicalTrials.gov

23. Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

    This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.

    Stage

    Phase 1

    Ages

    10 to 17

    Site

    BioXcel Clinical Research Site, Anaheim, California

    Locations

    5 in total

    Run by

    BioXcel Therapeutics Inc

    See if you can join NCT05025605 on ClinicalTrials.gov

24. Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia

    This study will investigate the effects of intermittent Theta Burst Stimulation (iTBS) on natural oscillatory frequency of the dorsolateral prefrontal cortex (DLPFC) and working memory in early-course schizophrenia (EC-SCZ). Transcranial magnetic stimulation (TMS) will be used to evoke oscillatory …

    Stage

    Not phased

    Ages

    18 to 40

    Site

    University of Pittsburgh, Pittsburgh, Pennsylvania

    Run by

    Fabio Ferrarelli

    See if you can join NCT05102929 on ClinicalTrials.gov

25. Improving Cognition Through Telehealth Aerobic Exercise and Cognitive Training After a First Schizophrenia Episode

    The participants in the study will receive psychiatric treatment at the UCLA Aftercare Research Program. All participants in this 12-month RCT will receive cognitive training. Half of the patients will also be randomly assigned to the aerobic exercise and strength training condition, and the other …

    Stage

    Not phased

    Ages

    18 to 45

    Site

    UCLA Aftercare Research Program, Los Angeles, California

    Run by

    University of California, Los Angeles

    See if you can join NCT05890183 on ClinicalTrials.gov